Products for Research Use Only
RegisterLogin

Belatacept

CAT: 0804-HY-108813-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-108813-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Belatacept (BMS 224818) is a selective T-cell costimulation blocker and a costimulator of the CD28-CD80/86 pathway. Belatacept binds to the CD 80/86 ligand and inhibits CD-28-mediated T cell costimulation and IFN-γ production. Belatacept can be used in studies of immunosuppression in organ transplantation[1][2]. The component ratio of this product is Active ingredient : Excipients = 1:2.4.
CAS Number
706808-37-9
Product Name Alternative
BMS 224818; LEA 29Y
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/belatacept.html
Purity
99.30
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
[Belatacept]
Molecular Weight
(90 kDa)
References & Citations
[1]George Melvin, et al. Belatacept: A worthy alternative to cyclosporine?. J Pharmacol Pharmacother. 2012 Jan-Mar; 3 (1) : 90–92. |[2]Gretchen N de Graav, et al. Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. PLoS One. 2016 Feb 26;11 (2) :e0148604. |[3]Hengcheng Zhang, et al. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation. Front Immunol. 2021 Feb 24;12:618737. |[4]Gretchen N de Graav, et al. Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. Front Immunol. 2017 May 31;8:641. |[5]laire Leibler, et al. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk. J Am Soc Nephrol. 2018 Mar;29 (3) :1049-1062. |[6]Christian P Larsen, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005 Mar;5 (3) :443-53.
Shipping Conditions
Isolate blue ice and the product with bubble pack to avoid direct contact
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched

Alternative Products

CatalogName
T64239-01Belatacept
051930-01Belatacept Biosimilar
GTR18291811-01Belatacept Antibody
E55B1305Belatacept (Reference antibody)
HW630026-01Research Grade Belatacept
GTR18696817-01Belatacept Monoclonal Antibody
MBS3030563-01Belatacept Biosimilar - Research Grade
PX-TA2005-01Belatacept Biosimilar - Anti-CD80, CD86 fusion protein - Research Grade
A135994Belatacept Biosimilar (, Fusion - [CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152) ]2 - IGHG1 Fc (Fragment constant) )

Popular Products